News | November 04, 2022
Sanofi India posts Q3CY22 net profit at Rs. 130.9 Cr
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
The company has reported total income of Rs. 703.3 crores during the period ended September 30, 2022
Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.
Futnani has over two decades of experience in delivering growth and transformation that spans several therapeutic areas.
Rodolfo brings with him a wealth of rich experience from commercial, marketing, and general management roles across several multinational companies
The company has reported total income of Rs.3031 crores during the calendar year ended December 31, 2021.
The Board of Directors of Sanofi India Limited, at its meeting held on October 26th 2021 have approved the unaudited Standalone financial results of the company for the period ended September 30, 2021
Cipla will be responsible for the distribution of Sanofi India's six CNS brands including Frisium
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Narayanan to lead SeQuent through next phase of consolidation and growth
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
Subscribe To Our Newsletter & Stay Updated
